DEF: Zentalis Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Zentalis Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, featuring director elections, auditor ratification, and executive compensation advisory vote.

Summary

• Zentalis Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, at 10:00 a.m. Eastern Time.
• Stockholders of record as of April 21, 2025, are entitled to vote on proposals including the election of three Class II directors, ratification of Ernst & Young LLP as the independent accounting firm, and an advisory vote on executive compensation.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of Ernst & Young and the advisory vote on executive compensation.
• The meeting will be a virtual webcast, accessible at www.virtualshareholdermeeting.com/ZNTL2025, with a 16-digit control number required for participation.
• As of the record date, 71,951,934 shares of Common Stock were outstanding and entitled to vote.
• The proxy materials are available online at www.proxyvote.com, and stockholders can request paper copies.
• The Board is divided into three classes, with Class II directors serving until the 2028 Annual Meeting.
• The nominees for Class II directors are Scott Myers, Karan Takhar, and Luke Walker, M.D.
• The Audit Committee has appointed Ernst & Young as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board seeks an advisory vote on the compensation of the named executive officers.
• The company has adopted a Policy for Recovery of Erroneously Awarded Compensation, or the Clawback Policy, that is intended to comply with the rules and regulations promulgated by the SEC and the Nasdaq listing standards that implement the clawback policy requirements set forth in Section 10D of the Exchange Act.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information and recommendations. The tone is professional and neutral, with a slight positive leaning due to the company's efforts to engage with stockholders and promote good governance.

Positives

• The company is providing a virtual meeting option to increase stockholder attendance and participation.
• Stockholders have multiple options for voting, including online, telephone, and mail.
• The company is taking advantage of SEC rules to furnish proxy materials over the Internet, reducing environmental impact and costs.
• The Board has adopted a Clawback Policy that provides for the mandatory recovery of erroneously awarded incentive-based compensation paid to any current or former executive officer of the Company in the event of a required accounting restatement.

Future Outlook

The document outlines the proposals to be voted on at the upcoming annual meeting, indicating the company's focus on corporate governance and shareholder engagement.

Management Comments

• Julie Eastland, President and CEO, urges stockholders to vote and submit their proxy.
• Julie Eastland thanks stockholders for their support to drive Zentalis' science and product candidates forward for cancer patients.

Industry Context

As a clinical-stage biopharmaceutical company, Zentalis' annual meeting and proposals reflect standard corporate governance practices within the industry, including director elections, auditor ratification, and executive compensation.

Comparison to Industry Standards

• The proposals outlined in the proxy statement, such as electing directors, ratifying the appointment of an independent accounting firm, and holding an advisory vote on executive compensation, are standard practices for publicly traded companies in the biopharmaceutical industry.
• Companies like Amgen (Nasdaq: AMGN) and Seagen (Nasdaq: SGEN) also hold annual meetings with similar proposals.
• The virtual format of the annual meeting aligns with a growing trend among companies to increase accessibility and reduce costs.
• The company's compensation policies, including the use of stock options and RSUs, are common practices in the biopharmaceutical industry to align executive interests with those of shareholders.

Management Changes

Corporate Governance

Related Party Transactions

• Transactions with Recurium IP Holdings, LLC, where former officers Dr. Kevin Bunker and Cam Gallagher are managing members.
• Transactions with Tempus Labs, Inc., where former CEO Dr. Kimberly Blackwell was previously employed and served as an advisor.
• Termination of collaboration and license agreements with Zentera Therapeutics, involving payments and return of equity stake.
• Acquisition of Series B convertible preferred stock of Kalyra Pharmaceuticals, Inc., where Karan Takhar, Dr. Kevin Bunker, and Cam Gallagher had affiliations.

Stakeholder Impact

• Stockholders have the opportunity to vote on key company matters, influencing the direction and governance of Zentalis Pharmaceuticals.
• Executive compensation decisions impact employee morale and motivation.
• The appointment of Ernst & Young as the independent accounting firm affects the credibility and reliability of financial reporting.
• The company's corporate governance policies, such as the Clawback Policy, promote transparency and accountability, benefiting all stakeholders.

Next Steps

• Stockholders to review proxy materials and vote on proposals.
• Company to hold the Annual Meeting on June 17, 2025.
• Company to report the final voting results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Ernst & Young, Executive Compensation, Virtual Meeting, Voting, Zentalis Pharmaceuticals, Governance